No abstract available

[en] Multiple parameters that contribute to the general immune competence were measured for 145 patients with bronchogenic carcinoma. These same parameters were measured for a group of healthy individuals to establish normal values for each of the tests of immunity. The immunoprofile data for the patients were analyzed on the basis of normal or abnormal measurements to determine the effects of stage of disease, histology, prior surgery and age of the patients on the immune system. A strong stage related correlation with immune impairment was observed in that an increased number of patients with perturbed immunity could be demonstrated for many of the parameters studied

No abstract available

No abstract available

No abstract available

No abstract available

[en] From August 1978 through December 1979, 51 patients with advanced non-oat cell carcinoma of the lung were enrolled in a Phase I/II trial sponsored by the Radiation Therapy Oncology Group (RTOG) employing misonidazole (a 2-nitroimidazole) as a hypoxic cell sensitizer and radiation. The purpose of this study was to test drug and radiation tolerance and to assess the short term efficacy of this unconventional treatment. Tumor doses of 600 rad were given twice weekly for three weeks for a total of 3600 rad, preceded four to six hours by misonidazole in a dose of 2 gm/m₂ or 1.75 gm/m₂, administered orally. Forty-nine patients were evaluable. Serious toxicity from this treatment was rare. Grade 2 or 3 peripheral neuro-toxicity occurred in eight of 24 patients (33%) with drug doses of 2 gm/m₂ and in four of 26 patients (15%) who received 1.75 gm/m₂. Grade 3 or 4 central nervous system toxicity occurred in two patients. Two patients developed serious late radiation complications: one patient had a transverse myelitis that appeared one year following delivery of 3600 rad to the spinal cord; a second patient developed a tracheoesophageal fistula and pericarditis eight months following treatment. Objective responses were reported in 67% of patients (complete in 18%); 70% of the patients died with a median survival time of nine months. Of 32 patients eligible for 12 month follow-up, 34% survived more than one year. Patterns of relapse after initial treatment and comparison with results from other RTOG trials using conventional fractionation are discussed

[en] Preliminary analysis was carried out on a prospective randomized cooperative group study involving 375 patients with histologically proven unresectable non-oat cell carcinoma of the lung who were treated with definitive radiotherapy. The patients were randomized to one of four treatment regimens: 4000 rad split course (2000 rad in five fractions one week, two weeks rest and an additional 2000 rad, five fractions in one week) or 4000, 5000 or 6000 rad continuous courses, five fractions per week. The patients who were treated with the split course had the lowest survival compared with the other groups. Complete and partial local tumor regression was 48% in patients who were treated with 4000 rad, 65% in the 5000 rad and 61% in the 6000 rad group. The rate of initial intrathoracic recurrence was 38% in patients who were treated with 6000 rad; 45% in those who received 5000 rad, 51% and 64% with 4000 rad split or continuous course, respectively. Distant metastases concurrent with or prior to intrathoracic failure were significantly higher in the patients with adenocarcinoma or large cell adenocarcinoma (63%) than in epidermoid carcinoma (33%). The present data strongly suggest that patients who were treated with 5000 or 6000 rad had a better response, tumor control and survival than those who were treated with lower doses